"10.1371_journal.pone.0058423","plos one","2013-03-14T00:00:00Z","Claude Jourdan Le Saux; Philip Davy; Christopher Brampton; Seema S Ahuja; Steven Fauce; Pooja Shivshankar; Hieu Nguyen; Mahesh Ramaseshan; Robert Tressler; Zhu Pirot; Calvin B Harley; Richard Allsopp","University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America; John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America; Geron Corporation, Menlo Park, California, United States of America; Cellerant, Redwood City, California, United States of America; Beckman Coulter, Inc., Brea, California, United States of America","Conceived and designed the experiments: RA CLS. Performed the experiments: RA PD CLS CB MR SF SA ZP PS HN. Analyzed the data: RA CLS PD CB SA SF PS HN. Contributed reagents/materials/analysis tools: RT ZP CBH RA CLS MR. Wrote the paper: RA CLS.","The authors have read the journal's policy and have the following conflict: Authors CBH, ZP, RT, SF and MR own stock in Geron Corporation, a company that is developing GRN510 as a potential drug. In addition, ZP and MR are affiliated with Geron Corp, CBH is affiliated with Telome-Health, SF is affiliated with Beckman-Coulter, and RT is affiliated with Cellerant. None of these affiliations alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","03","Claude Jourdan Le Saux","CJLS",12,TRUE,2,10,8,2,TRUE,TRUE,FALSE,0,NA,FALSE
